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Objectives: Alzheimer’s disease (AD) afflicts up to 9% of people aged 65 and over 
worldwide, with prevalence projected to increase. AD is associated with reduced 
quality of life and high treatment and management costs. A number of recently 
developed screening and preventative interventions offer reduction in resource use 
and improvement in quality of life for AD patients. The majority of existing models 
for economic evaluation of AD interventions focus on pharmaceuticals and due 
to their limited scope and time-horizon are unsuitable for evaluation of screening 
and preventative strategies. It is proposed to develop a decision model to ascertain 
the most cost-effective ‘mix’ of preventative and screening methods for Denmark. 
The objective of this study is to develop and validate such a model for economic 
evaluation of non-pharmaceutical interventions for AD MethOds: A Markov model 
was developed, representing transitions of a hypothetical cohort of 65 year olds 
from ‘no AD’ to different stages of AD (Very Mild through to Severe). AD could either 
be ‘identified’ or ‘not identified’ to reflect the difference in costs associated with 
treatment and management. Due to absence of Danish data, the model utilised 
transition probabilities based on US data; AD-associated costs and utilities were 
obtained from Danish and Swedish data, respectively. The model was externally vali-
dated against an epidemiological study of AD in Denmark to predict prevalence and 
stage of AD by age. Results: The model accurately predicted Danish age-specific 
prevalence of AD, although the prevalence for the 75-79 age group was overesti-
mated by 3%. The model also produced accurate predictions of the distribution of 
AD severity. cOnclusiOns: The model provides a simple and robust framework 
for economic evaluation of screening and other non-pharmaceutical interventions 
for AD. The lack of up to date epidemiological data on AD is a challenge for model 
validation and introduces uncertainty.
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Objectives: Diabetes is known to be associated with a considerable decline in life 
expectancy (LE). The aim of this study was to use a modelling approach to assess 
LE in low, intermediate and high-risk type-2-diabetes (T2D) populations and to 
compare these to observations from the Canadian-Chronic-Disease-Surveillance-
System (CCDSS). MethOds: This study used the IMS-Core-Diabetes-Model (CDM), 
a validated diabetes simulation model, to project the LE of T2D individuals with a 
low-risk (age= 55, diabetes duration= 5, no CVD history), intermediate-risk (age= 65, 
diabetes duration= 15, moderate CVD history) and high-risk profile (age= 80, diabetes 
duration= 30, advanced CVD history). LE was predicted utilising three alternative 
mortality risk prediction models (RPMs) from the UKPDS 68 study (UK68), the UKPDS 
82 study (UK82) and a risk equation based on Western Australia (WA) administrative 
data. Life-years-lost (LYL) in diabetes vs. no-diabetes populations was estimated 
based on the difference in age matching LE obtained from UK-national-life-tables 
subtracted by CDM projected-LE. Results were finally contrasted to LE and LYL esti-
mations from the CCDSS study. Results: When UK68 mortality RPMs were applied, 
LE projected was 23.29, 15.94 and 7.78 years for the low, intermediate and high risk 
cohort. This compared to 22.16, 14.88 and 7.29 years utilising UK82 RPMs and 25.94, 
18.11 and 9.05years when utilising the WA RPMs. Based on UK life table data, LYL in 
diabetes vs. no-diabetes populations were 4.76, 3.61 and 1.11 (UK68), 5.89, 4.67 and 
1.60 (UK82) and 2.11, 1.44 and -0.15 (WA) years. The CCDSS study reported outcomes 
for the low risk (age 55) and high risk (age 80) profile at 24.5 and 8.3 years (LE) and 5.5 
and 2.25 years (LYL), respectively. cOnclusiOns: UKPDS based models predicted 
LE and LYL very closely to CCDSS study findings. The Western Australian RPM seems 
not to be applicable to a UK and Canadian population.
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Objectives: Cost-effectiveness (CE) is increasingly used for resource allocation 
worldwide. One key hurdle for its widespread use is the lack of a widely accepted 
methodology to derive thresholds at the healthcare system (HS) or country level. 
The objective is to propose a methodology and derive local CE thresholds based 
on per capita health expenditures (pcHE) and life expectancy (LE). MethOds: 
Our approach is based on the relationship between pcHE and LE; assuming that 
the increase in expenditures reflects the CE of the interventions added to reach 
current LE. For HS willing to maintain or increase their secular trend of raising 
pcHE in order to improve health, the threshold (measured in units of pcHE) will 
be: Threshold= (LE+1)*i-LE; where LE is measured in life-years (LY) or QALYs; and 
“i” is the ratio of increase in pcHE that the HS is willing to accept to increase LE 
by one unit (eg i= 1.09 for a 9% increase). For HS with cost-containment man-
dates: Threshold= LE-((LE-1)/i), where “i” represents the past increase in pcHE to 
gain the last unit of LE. We used OLS to predict “i” for 185 countries, following 
both a cross-sectional (2013) and a longitudinal approach (2003-2013) using World 
Bank data. Results: Depending on income strata and LE, countries can expect to 
increase pcHE by 7-10% for an additional LY and between 10-13% for an additional 
QALY. This represent cost per QALY thresholds ranging from 9-11 pcHE in High-
Income to 5-8 in Low-Income countries, which translates to thresholds of 32-40 
thousands US dollars in UK; 83-101 in USA; 6-7 in Mexico and 0.5 in Uganda (around 
0.9, 1.8, 0.6 and 0.7 GDP per capita respectively). cOnclusiOns: This approach, 
based on widely available data, can be useful to inform decisions in all countries 
using economic evaluations. Our results show thresholds usually lower than those 
promoted by WHO.
deaths attributable to AAA in Italy represented 28.0% of the 5EU total, despite 
Italy accounting for only 19.3% of the 5EU population in 2013. cOnclusiOns: Our 
study reveals that the burden of AAA among the 5EU markets is most severe in 
Italy, which accounted for the highest number of both prevalent cases and deaths 
attributable to AAA in the 5EU. Throughout the 5EU, females accounted for a dis-
proportionately high percentage of deaths despite constituting a low percentage 
of prevalent cases. Consequently, current screening guidelines should target both 
sexes, rather than males only.
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Objectives: Published literature suggests that treatment escalation to natali-
zumab, in relapsing-remitting multiple sclerosis (RRMS) patients with inad-
equate response to first-line injectable treatments, is clinically more effective 
than switching among immunomodulators. This analysis evaluates the cost-
effectiveness of escalation vs. switching, adopting the Italian social perspec-
tive. MethOds: A lifetime horizon Markov model compared early escalation to 
natalizumab vs. switching among immunomodulators (interferons or glatiramer 
acetate) followed by escalation to natalizumab, in a cohort of patients who failed 
a first-line therapy. Specifically the two compared treatment algorithms were: 
a) escalation until progression of Expanded Disability Status Scale (EDSS) score 
of 7.0; b) switching until EDSS= 4.0, followed by escalation until EDSS= 7.0. For 
the two options, the model analyzed social costs and quality adjusted survival 
(QALYs). The model captured the effects of therapies in prolonging time without 
disability progression and burden of relapses. Clinical data was derived from a 
published study comparing the two treatment strategies. Unit tariffs and costs 
were adapted to the Italian setting. Results: Early escalation to natalizumab 
was dominant over switching among immunomodulators. The two options led to 
similar costs (€ 1.008 mln/patient in the escalation group, vs. € 1.034 mln/patient 
in the switching group), but early escalation was associated to prolonged qual-
ity adjusted survival (11.54 vs. 9.94 QALYs; +16.05%). A slight overall survival 
increase was also observed (21.14 vs. 20.80 life years). The increased acquisi-
tion costs related to prolonged treatment with natalizumab were offset by sav-
ings due to decreased burden of relapses and a reduction of disability-related 
costs. cOnclusiOns: Early escalation to natalizumab is a cost-effective option 
in RRMS patients who don’t adequately respond to conventional immunomodula-
tors compared to switching among immunomodulators and escalation later. This 
shows that patients benefit from early escalation to natalizumab and prolonging 
immunomodulation, using therapies with similar mechanisms of action, could 
determine inappropriate usage of economic resources and poor benefit for 
patients.
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Objectives: Cardiovascular disease (CVD) risk prediction models are available 
for the general population (Framingham) and for type-2-diabetes (T2D) (UKPDS 
68 and 82) but may not be appropriate in type-1-diabetes (T1D). The IMS CORE 
Diabetes Model (CDM) uses Framingham and UKPDS risk equations (REs) to pre-
dict CVD incidence in T2D and has recently been updated to include two CVD 
risk prediction approaches specific to T1D populations based on data from the 
Epidemiology-of-Diabetes-Interventions-and-Complications-study (EDIC) and 
a novel RE from the Pittsburgh-Epidemiology-of-Diabetes-Complications-Study 
(PEDC). The objective of this study was to compare CVD incidence across T1D 
model projections utilizing UKPDS, EDIC and PEDC REs and compare these to pub-
lished EDIC findings. MethOds: The CDM was applied to project the incidence of 
myocardial-infarction (MI), stroke, heart-failure (HF) and ischemic-heart-disease 
(IHD) utilizing three alternative CVD REs, the UKPDS 68 RE (UK68-RE), EDIC-RE 
and PEDC-RE. The risk profile of a newly diagnosed T1D population (age 21 years, 
HbA1c 7%, systolic-blood-pressure 114 mmHg, body-mass-index 32 Kg/m2, high-
density-lipoprotein 45 mg/dl and total-cholesterol 170 mg/dl) was projected over 
30 years. The incidence of total CVD was estimated as the sum of the individual 
composites (%CVD= %MI+%stroke+IHD+HF) to enable comparison to published 
EDIC findings. Results: When UK68-REs were applied, the 30-year cumulative 
incidence of CVD for a newly diagnosed T1D individual was projected at 2.66%, 
0.27%, 3.88% and 0.72% for MI, stroke, IHD and HF, respectively. This compared to 
4.10%, 0.66%, 3.36 and 0.58% utilizing EDIC-RE and 5.27%, 1.01%, 3.44 and 1.18% 
utilizing PEDC-RE. Total predicted CVD incidence added up to 7.53%, 8.70% and 
10.90% for UK68-RE, EDIC-RE and PEDC-RE respectively, which compares to 8.70% 
incidence of CVD as observed during the EDIC study. cOnclusiOns: As expected, 
the CDM reproduced the published EDIC CVD incidence when using the EDIC 
approach but demonstrated a slight underestimation utilizing UK68-RE and over-
estimation with PEDC-RE.
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insights on model constructs, key data elements/assumptions, and recent mod-
eling advances. Results: Thirty-three HTAs comprising 60 CUAs were considered 
relevant and investigated further. Albeit individual sampling models and discrete 
event simulations have some advantages over Markov models, these three tech-
niques may provide similar cost-effectiveness estimates and were all deemed 
appropriate for HTA submissions. At least ten different structural components 
were identified for which data sources and/or assumptions have evolved over time, 
several of which have a major bearing on model outcomes. The characteristics of 
patients entering the model (e.g. disease severity and prior treatments), assump-
tions about long-term disease progression whilst on treatment and the rebound 
effect upon treatment discontinuation, and mapping of Health Assessment 
Questionnaire and/or pain scores to Quality of Life utility values were repeatedly 
mentioned as key elements affecting the results. cOnclusiOns: A wide variety 
of economic models for the evaluation of bDMARDS in RA have been developed 
and are continuously being refined. Despite recent initiatives to reach consensus 
on how RA models should be designed, substantial differences in the data sources 
and assumptions that are used still remain. This limits the comparability across 
and also generalizability of the various results obtained by using these models 
and poses problems to all stakeholders involved in HTAs.
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Objectives: One of the major critiques with submitted manufacturer’s cost-
effectiveness models is surrounding the structural uncertainty. However, methods 
dealing with structural uncertainties are not well-developed, even though these 
might have a significant impact on model results. This study investigates the 
impact of structural changes in a National Institute for Health and Care Excellence 
(NICE) single technology appraisal cost-effectiveness model of Erlotinib versus 
Best Supportive Care as a maintenance therapy for patients with non-small cell 
lung cancer. The manufacturer’s model submission was criticised for having a 
“Markov” model not governed by transition probabilities. It considered an inde-
pendent projective survival functions for progression-free survival and overall 
survival, which allowed a negative post-progression survival (PPS) estimate to 
appear in later cycle. MethOds: Using published summary survival data, this 
study adopted three approaches, covering both fixed- and time-varying, to esti-
mate health state transition probabilities that are used in a restructured Markov 
model. Results: Unlike for placebo, the parametric approach estimates post-
progression probabilities and probabilities of death for Erlotinib differently than 
fixed-transition approaches. The best fitting curves are achieved for both PPS 
and probability of death across the time for which data were available, but the 
curves start diverging towards the end of this period. The alternative (Markov) 
model which extrapolates the curves forward in time suggests that this differ-
ence between a time-varying and fixed-transition becomes even greater. The 
alternative models produce an Incremental Cost-Effectiveness Ratio (ICER) 
of £54k -£66k per quality adjusted life year (QALY) gain, which is comparable 
to an ICER presented in the MS (£55k/QALY gain). cOnclusiOns: The results 
from restructured alternative models do not suggest different cost-effectiveness 
results to those reported in the manufacturer submission; however, in terms of 
magnitude they vary. This variation in cost-effectiveness results produced by 
restructured models might be crucial for interventions falling near a threshold 
value.
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Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic 
disorder characterised by enlarged kidneys and declining renal function. ADPKD 
progression rates are heterogeneous, influenced by age, gender, renal size and 
genotype. Disease models often utilise progression rates derived from published 
studies. This study aimed to compare ADPKD progression, in terms of changes in 
total kidney volume (TKV) and renal function, modelled from summary versus 
patient-level data (PLD), and assess the consistency of predictions with trial obser-
vations. MethOds: Regression equations were derived from the TEMPO 3:4 trial 
placebo arm (natural history) to predict annual changes in TKV and estimated glo-
merular filtration rate (eGFR). Candidate covariates included age, gender, ethnicity, 
region/country, TKV and eGFR. Predictions were compared using the PLD regres-
sion equations or linear interpolation of summary rates of change in four patient 
categories. Finally, the model was initiated with published baseline patient pro-
files representing early and late disease from the HALT-PKD trials, and predicted 
progression compared to trial observations. Results: For patients initiated with 
the average TEMPO 3:4 placebo profile, predicted eGFR trajectories based on PLD 
or summary data were similar (average decline: -5.3 and -5.1ml/min/1.73m2/year, 
respectively); however, TKV predictions deviated as TKV exceeded 2,500ml, with 
increasingly rapid growth predicted based on summary data. The model closely 
replicated ADPKD progression among patients with early disease; all predicted 
values within the 95% confidence interval of HALT-PKD observations. In patients 
with late disease, modelled baseline TKV of 1,000-1,500ml led to closest replication 
of eGFR observations (average decline: -3.2 to -4.4, versus -3.9ml/min/1.73m2/year 
during trial). cOnclusiOns: Though predictions based on summary and PLD 
were consistent, the PLD regression equations produced more realistic results at 
extreme values. The availability of relevant PLD to describe the natural history of 
ADPKD progression provides a more robust foundation for disease and economic 
modelling than summary data alone.
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Objectives: To address the practical and methodological issues associated with 
using low-quality evidence outcomes in health economic modelling. MethOds: A 
cost-effectiveness model for disease-modifying drugs (DMDs) in multiple sclerosis 
(MS) in The Netherlands was used to assess how to deal with low-quality evidence 
in health economic modelling. The model adopted a 10-year time horizon and a 
societal perspective. A Markov model was constructed based on EDSS staging in 
MS, including relapse. The central focus was on disease progression — instead of 
relapse — which appeared to be the driver of the cost-effectiveness outcomes. The 
main data source was a recent Cochrane review estimating relative efficacy and 
acceptability of DMDs in relapse-remitting MS. Other data sources included addi-
tional published literature, clinical trials, and official price/tariff lists. Results: The 
analysis based on the Cochrane review data showed that interferon beta-1a-R (Rebif) 
is cost-effective over interferon beta-1a-A (Avonex) (dominant) and interferon beta-
1b (€ 27,654/QALY), but that interferon beta-1a-R is not cost-effective over glatiramer 
acetate. However, for disease progression, the level of evidence is considered very 
low (level 1) for all drugs, except interferon beta-1a-R (moderate - level 3), implying 
unreliable effectiveness outcomes which, consequently, can result in unreliable 
cost-effectiveness outcomes. Two reasonable alternative approaches may be to 
exclude very low evidence from the cost-effectiveness analysis or assume placebo 
efficacy. Alternative analyses, including placebo efficacy for disease progression for 
drugs of which the evidence is labelled very low by Cochrane (all except interferon 
beta-1a-R), strongly impacted outcomes: interferon beta-1a-R was cost-effective 
over interferon beta-1a-A (dominant), interferon beta-1b (€ 6,265), and glatiramer 
acetate (dominant). cOnclusiOns: Inclusion of very low-quality evidence in health 
economic modelling may lead to unreliable cost-effectiveness conclusions. However, 
a gold standard is lacking for handling levels of clinical evidence in health economic 
models. One alternative, presented here, would be to assume placebo efficacy in 
such cases.
PRM77
best PRaCtiCes foR netWoRk Meta-analysis Methodology: 
CoMPaRatiVe effeCtiVeness of inteRfeRon-beta theRaPies in 
RelaPsing-ReMitting MultiPle sCleRosis
Beckerman R1, Locklear JC2, Jiang Y3, Solon C4, Smith NJ3, Phillips AL2
1Maple Health Group, LLC, New York, NY, USA, 2EMD Serono, Inc., Rockland, MA, USA, 
3CBPartners, New York, NY, USA, 4CBPartners, San Francisco, CA, USA
Objectives: To evaluate different statistical methodologies in a network meta-
analysis (NMA) comparing the effectiveness of interferon-beta (IFNβ ) therapies 
across several endpoints in relapsing-remitting multiple sclerosis (RRMS) to 
determine potential best practices. MethOds: A systematic literature review 
(1996-2014) was conducted to identify randomised, controlled trials of FDA- and 
EMA-approved IFNβ DMDs in RRMS, including subcutaneous (SC) IFNβ -1a (44μ g or 
22μ g 3x/wk), SC pegIFNβ -1a (125μ g every 2wks), intramuscular (IM) IFNβ -1a (30μ g 
1x/wk), and SC IFNβ -1b (250μ g EOD). Data were extracted for patients relapse-free, 
patients without disability progression, and patients without new MRI activity 
at study end. A random-effects Bayesian model was utilised for the base case 
analysis, and sensitivity analyses investigated results using different analysis 
frameworks or effects distributions. Results: 644 articles were retrieved; 14 met 
inclusion criteria and reported evaluable data. The evidence networks had few 
connections between nodes, with a maximum of 10 connections for the proportion 
of “patients relapse-free” endpoint. In addition, there were few connections with 
multiple studies linking nodes, with a maximum of 50% (5/10) of connections hav-
ing more than one study on the relapse endpoint, and there were at most two stud-
ies linking any two nodes. Because of the small number of studies linking nodes, 
a random-effects Bayesian model with uninformative priors resulted in wide 
credible intervals, complicating interpretation of results; uncertainty decreased 
using a random-effects Bayesian model with an informative prior as well as with 
a fixed-effects Bayesian model. Estimates for the treatment effects were similar 
across all Bayesian approaches. Utilising a Frequentist approach resulted in similar 
estimates for treatment effects compared to the Bayesian analyses framework, 
although with slightly less uncertainty. cOnclusiOns: While similar estimates 
for treatment effects were found across statistical methodologies, the combi-
nation of a Bayesian approach and a random-effects distribution with informa-
tive prior allowed for methodological robustness while yielding interpretable 
findings.
PRM78
ReVieW of eConoMiC Models foR the eValuation of biologiC dMaRds 
in RheuMatoid aRthRitis
Van Laer J1, Gubbels L2, Rodriguez IL3, Maervoet J4, Nijhuis T2, Nielsen AT5, Peterson S6, 
Hemels M5, Ganguly R7
1Janssen Pharmaceutica N.V., Beerse, Belgium, 2Quintiles Advisory Services, Hoofddorp, The 
Netherlands, 3Quintiles Consulting, Reading, UK, 4Quintiles Consulting, Vilvoorde, Belgium, 
5Janssen-Cilag A/S, Birkerød, Denmark, 6Janssen, Horsham, PA, USA, 7GlaxoSmithKline, King of 
Prussia, PA, USA
Objectives: Over the last decade, several biologic disease-modifying anti-
rheumatic drugs (bDMARDs) have become available providing additional treat-
ment options for rheumatoid arthritis (RA) patients. This study was conducted 
to identify and compare existing economic models used by health technology 
assessment (HTA) bodies to evaluate bDMARDs. MethOds: The HTA Accelerator 
database and websites of HTA agencies (NICE, SMC, NCPE, ZIN, TLV, PBAC, CADTH, 
INESSS, MOHLTC, DECIT-CGATS and AHRQ) were screened to identify assess-
ments of bDMARDs published since 2005 that included a cost-utility analysis 
(CUA). In addition, a targeted literature review was performed to gain further 
